FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885817833> ?p ?o ?g. }

• W2885817833 endingPage "1161" @default.
• W2885817833 startingPage "1153" @default.
• W2885817833 abstract "Abstract Anthracyclines have been a mainstay of breast cancer therapy for decades, with strong evidence demonstrating their impact on breast cancer survival. However, concerns regarding rare but serious long-term toxicities including cardiotoxicity and hematologic malignancies have driven interest in alternative adjuvant therapy options with more favorable toxicity profiles. This article provides an update of data that help inform clinicians of the role anthracyclines should play in adjuvant breast cancer therapy. Two recently reported large randomized trials—the Anthracycline in Early Breast Cancer and Western German Study Plan B studies—compared a taxane and cyclophosphamide regimen with an anthracycline, taxane, and cyclophosphamide regimen. Although the studies had conflicting results, together these studies suggest that the benefit of adjuvant anthracycline therapy over a nonanthracycline taxane-containing regimen is modest at best and may be primarily seen in patients with especially high-risk disease (i.e., triple-negative breast cancer, involvement of multiple lymph nodes). A third study—the MINDACT study—compared an anthracycline-based regimen to a nonanthracycline regimen, with similar outcomes in both groups. Despite the toxicities, no adjuvant breast cancer regimen has been shown to be superior to an anthracycline-taxane regimen in high-risk patients. These data can directly inform clinical decision-making in determining which patients warrant use of adjuvant anthracycline therapy. Future research may focus on confirming subgroups for whom it is reasonable to forgo adjuvant anthracyclines and validating predictive biomarkers or scores for anthracycline benefit. Implications for Practice In patients with early breast cancer, the choice of adjuvant chemotherapy should be based on its effectiveness in reducing breast cancer recurrences and its short- and long-term toxicities. Although adjuvant anthracycline and taxane chemotherapy has the most data supporting its effectiveness, anthracyclines carry a small but important increased risk for cardiotoxicity and leukemia. Two recent clinical trials help describe the degree of benefit with adjuvant anthracycline therapy compared with taxane therapy alone. They suggest that in patients with hormone receptor-positive breast cancer and limited lymph node involvement, nonanthracycline taxane-based adjuvant therapy may be adequate." @default.
• W2885817833 created "2018-08-22" @default.
• W2885817833 creator A5042066908 @default.
• W2885817833 creator A5085028425 @default.
• W2885817833 date "2018-08-17" @default.
• W2885817833 modified "2023-10-12" @default.
• W2885817833 title "Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?" @default.
• W2885817833 cites W1492360552 @default.
• W2885817833 cites W1701849548 @default.
• W2885817833 cites W1828224642 @default.
• W2885817833 cites W1848579801 @default.
• W2885817833 cites W1861752845 @default.
• W2885817833 cites W1882532563 @default.
• W2885817833 cites W1926958054 @default.
• W2885817833 cites W1980522764 @default.
• W2885817833 cites W1987593270 @default.
• W2885817833 cites W1994791499 @default.
• W2885817833 cites W2005857146 @default.
• W2885817833 cites W2009552163 @default.
• W2885817833 cites W2017888462 @default.
• W2885817833 cites W2040935952 @default.
• W2885817833 cites W2044053813 @default.
• W2885817833 cites W2045216597 @default.
• W2885817833 cites W2045324973 @default.
• W2885817833 cites W2046425687 @default.
• W2885817833 cites W2050629268 @default.
• W2885817833 cites W2082751083 @default.
• W2885817833 cites W2087954557 @default.
• W2885817833 cites W2095861620 @default.
• W2885817833 cites W2096471659 @default.
• W2885817833 cites W2098775844 @default.
• W2885817833 cites W2098898117 @default.
• W2885817833 cites W2108292279 @default.
• W2885817833 cites W2114610794 @default.
• W2885817833 cites W2116044878 @default.
• W2885817833 cites W2116280772 @default.
• W2885817833 cites W2116692581 @default.
• W2885817833 cites W2119416636 @default.
• W2885817833 cites W2121733532 @default.
• W2885817833 cites W2129736317 @default.
• W2885817833 cites W2135800076 @default.
• W2885817833 cites W2140074016 @default.
• W2885817833 cites W2143305439 @default.
• W2885817833 cites W2146384083 @default.
• W2885817833 cites W2147415463 @default.
• W2885817833 cites W2147558172 @default.
• W2885817833 cites W2147660572 @default.
• W2885817833 cites W2149708286 @default.
• W2885817833 cites W2149876820 @default.
• W2885817833 cites W2149908785 @default.
• W2885817833 cites W2167341447 @default.
• W2885817833 cites W2190954851 @default.
• W2885817833 cites W2208824773 @default.
• W2885817833 cites W2335332412 @default.
• W2885817833 cites W2434209561 @default.
• W2885817833 cites W2517421365 @default.
• W2885817833 cites W2517647639 @default.
• W2885817833 cites W2594905920 @default.
• W2885817833 cites W2597724168 @default.
• W2885817833 cites W2606920283 @default.
• W2885817833 cites W2623943749 @default.
• W2885817833 cites W2626563164 @default.
• W2885817833 cites W2630737569 @default.
• W2885817833 cites W2725076065 @default.
• W2885817833 cites W2767600184 @default.
• W2885817833 cites W2779944044 @default.
• W2885817833 cites W2901368272 @default.
• W2885817833 doi "https://doi.org/10.1634/theoncologist.2017-0672" @default.
• W2885817833 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6263120" @default.
• W2885817833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30120159" @default.
• W2885817833 hasPublicationYear "2018" @default.
• W2885817833 type Work @default.
• W2885817833 sameAs 2885817833 @default.
• W2885817833 citedByCount "40" @default.
• W2885817833 countsByYear W28858178332018 @default.
• W2885817833 countsByYear W28858178332019 @default.
• W2885817833 countsByYear W28858178332020 @default.
• W2885817833 countsByYear W28858178332021 @default.
• W2885817833 countsByYear W28858178332022 @default.
• W2885817833 countsByYear W28858178332023 @default.
• W2885817833 crossrefType "journal-article" @default.
• W2885817833 hasAuthorship W2885817833A5042066908 @default.
• W2885817833 hasAuthorship W2885817833A5085028425 @default.
• W2885817833 hasBestOaLocation W28858178331 @default.
• W2885817833 hasConcept C121608353 @default.
• W2885817833 hasConcept C126322002 @default.
• W2885817833 hasConcept C143998085 @default.
• W2885817833 hasConcept C2776694085 @default.
• W2885817833 hasConcept C2776755627 @default.
• W2885817833 hasConcept C2776802502 @default.
• W2885817833 hasConcept C2777511904 @default.
• W2885817833 hasConcept C2777863537 @default.
• W2885817833 hasConcept C2777982462 @default.
• W2885817833 hasConcept C2781413609 @default.
• W2885817833 hasConcept C530470458 @default.
• W2885817833 hasConcept C71924100 @default.
• W2885817833 hasConceptScore W2885817833C121608353 @default.
• W2885817833 hasConceptScore W2885817833C126322002 @default.

• next